Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Stian Knappskog; Per E Lønning

doi:10.4161/trns.2.5.16813

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Transcription. 2011 Sep-Oct;2(5):207-10. doi: 10.4161/trns.2.5.16813.

Authors

Stian Knappskog¹, Per E Lønning

Affiliation

¹ Section of Oncology, Institute of Medicine, University of Bergen; Bergen, Norway. [email protected]

Abstract

The proto-oncogene MDM2 inhibits p53 and plays a key role in cell growth control and apoptosis. Identification of two antagonizing MDM2 polymorphisms, SNP285 and SNP309, affecting cancer risk through modulation of Sp1 transcription factor binding, shed new light on the biological activity and phylogeny of this gene.

Publication types

Review

MeSH terms

Humans
Neoplasms* / etiology
Neoplasms* / genetics
Neoplasms* / pathology
Polymorphism, Single Nucleotide*
Protein Binding / genetics
Proto-Oncogene Mas
Proto-Oncogene Proteins c-mdm2 / genetics*
Proto-Oncogene Proteins c-mdm2 / metabolism
Risk Factors
Sp1 Transcription Factor / genetics*
Sp1 Transcription Factor / metabolism
Transcription, Genetic
Tumor Suppressor Protein p53 / metabolism

Substances

MAS1 protein, human
Proto-Oncogene Mas
Sp1 Transcription Factor
Tumor Suppressor Protein p53
MDM2 protein, human
Proto-Oncogene Proteins c-mdm2